GEA
LGND icon

Glen Eagle Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Glen Eagle Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-48
Closed -$4.08K – 663
2017
Q3 		$4.08K Hold
48
– – ﹤0.01% 540
2017
Q2 		$3.64K Hold
48
– – ﹤0.01% 504
2017
Q1 		$3.17K Buy
+48
New +$3.16K ﹤0.01% 491

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Glen Eagle Advisors's LGND Position: Q4 2017 in Review

Glen Eagle Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 48 shares — an estimated $4.08K sold.

Glen Eagle Advisors first reported a position in LGND in Q1 2017 and held it in 3 quarters. The position peaked at $4.08K in Q3 2017. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

  • Glen Eagle Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Glen Eagle Advisors sold 48 Ligand Pharmaceuticals shares in Q4 2017, an estimated $4.08K.
  • Glen Eagle Advisors first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Glen Eagle Advisors's Ligand Pharmaceuticals position peaked at $4.08K in Q3 2017.
  • 298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Glen Eagle Advisors's 13F filing for Q4 2017, filed 13 Aug 2024.